Moderna, Inc.’s initial deals for purchases of mRNA-1273, its messenger RNA (mRNA) vaccine against SARS-CoV-2, set a relatively high per-dose price of $32-$37. However, these first deals with smaller governments total just $400m to date, as opposed to the multibillion-dollar deals the US has made with other vaccine makers, and in those kinds of high-volume deals the company said its price per dose is likely to be lower.
Pfizer Inc. and BioNTech SE effectively set a $19.50 price per dose last month with the $1.95bn deal they negotiated with the US for 100 million doses of their competing mRNA vaccine, which like Moderna’s program entered Phase III testing at the end of July. (Also see "Pfizer’s US Contract Sets The Financial Bar For COVID-19 Vaccines" - Scrip, 22 July, 2020
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?